Evidence map›Paper›PMID 36831615›Full record

ArticleCancers2023

Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UK.

Samuel Oxley, Ashwin Kalra, Michail Sideris, Nicole Itzkowitz, Olivia Evans, Emma Christine Atakpa, Adam R Brentnall, Nina Dworschak, Faiza Gaba, Rhian Gabe and 11 more

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Global determinants of gynecologic cancer incidence and mortality: A cluster-based analysis with predictive insights.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Samuel OxleyWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.ORCID 0000-0003-1967-813X
Ashwin KalraWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.ORCID 0000-0002-5541-226X
Michail SiderisWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.ORCID 0000-0002-4199-6700
Nicole ItzkowitzWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Olivia EvansWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Emma Christine AtakpaWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Adam R BrentnallWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Nina DworschakWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Faiza GabaDepartment of Gynaecological Oncology, Royal London Hospital, Barts Health NHS Trust, London E1 1BB, UK.
Rhian GabeWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.ORCID 0000-0002-0273-3094
Sudha SundarInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.ORCID 0000-0002-5843-3015
Nick WoodLancashire Teaching Hospitals NHS Foundation Trust, Preston PR2 9HT, UK.
Shibani NicumInstitute of Cancer Research, University College London, London WC1E 6DD, UK.
Alexandra TaylorRoyal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Stephen DobbsBelfast City Hospital, Belfast Health and Social Care Trust, Belfast BT9 7AB, UK.
W Glenn McCluggageDepartment of Pathology, Belfast Health and Social Care Trust, Belfast BT12 6BA, UK.
Andy NordinEast Kent Gynaecological Oncology Centre, Queen Elizabeth the Queen Mother Hospital, Margate CT9 4AN, UK.
Rosa LegoodDepartment of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK.
Sean KehoeInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Sadaf Ghaem-MaghamiFaculty of Medicine, Department of Surgery & Cancer, Imperial College London, London SW7 2AZ, UK.ORCID 0000-0002-7369-5080
Ranjit ManchandaWolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.ORCID 0000-0003-3381-5057

Funding

British Gynaecological Cancer Society EMSG1L5R
6 · The paper itself

Abstract

backgroundThis study aimed to assess the impact of multiple COVID-19 waves on UK gynaecological-oncology services.

methodsAn online survey was distributed to all UK-British-Gynaecological-Cancer-Society members during three COVID-19 waves from 2020 to2022.

resultsIn total, 51 hospitals (including 32 cancer centres) responded to Survey 1, 42 hospitals (29 centres) to Survey 2, and 39 hospitals (30 centres) to Survey 3. During the first wave, urgent referrals reportedly fell by a median of 50% (IQR = 25-70%). In total, 49% hospitals reported reduced staffing, and the greatest was noted for trainee doctors, by a median of 40%. Theatre capacity was reduced by a median of 40%. A median of 30% of planned operations was postponed. Multidisciplinary meetings were completely virtual in 39% and mixed in 65% of the total. A median of 75% of outpatient consultations were remote. By the second wave, fewer hospitals reported staffing reductions, and there was a return to pre-pandemic urgent referrals and multidisciplinary workloads. Theatre capacity was reduced by a median of 10%, with 5% of operations postponed. The third wave demonstrated worsening staff reductions similar to Wave 1, primarily from sickness. Pre-pandemic levels of urgent referrals/workload continued, with little reduction in surgical capacity.

conclusionCOVID-19 led to a significant disruption of gynaecological-cancer care across the UK, including reduced staffing, urgent referrals, theatre capacity, and working practice changes. Whilst disruption eased and referrals/workloads returned to normal, significant staff shortages remained in 2022, highlighting persistent capacity constraints.

Indexed as

COVID-19gynaecological cancermultidisciplinary team

Identifiers

PMID36831615
PMCPMC9953843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.